DTI-Voodoo: machine learning over interaction networks and ontology-based background knowledge predicts drug-target interactions

WDGBANDTI: A Deep Graph Convolutional Network-Based Bilinear Attention Network for Drug-Target Interaction Prediction with Domain Adaptation

BACKGROUNDS

During the development of new drugs, it is essential to assess their effectiveness and examine the potential mechanisms behind side effects. This process typically involves combining the analysis of drugs under development with relevant existing drugs to more precisely evaluate the effects of drugs and targets. The use of deep learning methods to analyze this problem is currently a research hotspot, but several limitations remain: (i) how to deepen the analysis from the molecular level to the atomic level and analyze the key substructures that affect interactions on the basis of pharmaceutical mechanisms; (ii) how to integrate biomedical analysis with deep learning methods to make it medically sound and enhance interpretability.

METHODS

To address the limitations of existing research, based on Deep Graph Convolutional Network (Deep-GCN) and Bilinear Attention Network (BAN), we have constructed an interpretable deep learning framework, WDGBANDTI, to analyze and predict drug‒target interactions at the substructure level and enhance the prediction capability of the model with respect to unidentified target pairings by adding modules.

RESULTS

For different application scenarios, we validated the model via several commonly used and highly covered datasets. We also selected several state-of-the-art computer methods as comparison objects, and our model demonstrates advantages in accuracy, sensitivity, specificity, and other deep learning features. More importantly, the model can identify the substructures that play a role in drug‒target interactions through BAN, highlighting its excellent interpretability.

CONCLUSION

In conclusion, we believe that our work will contribute to advancements in drug development and side effect experiments and provide meaningful guidance for drug design.

MGMA-DTI: Drug target interaction prediction using multi-order gated convolution and multi-attention fusion

Accurately predicting drug-target interactions (DTI) is crucial for drug discovery and can reduce drug development costs. Recent deep learning-based DTI predictions have demonstrated promising performance, but they still face two challenges: (i) The over-reliance on the extraction of local features and insufficient learning of global features limit the model's performance. (ii) The lack of effective fusion of drug-target interaction features leads to the lack of interpretability of the model. To address these challenges, we propose a new model for predicting drug-target interactions based on multi-order gated convolution and multi-attention fusion, MGMA-DTI. The drug feature encoder obtains a two-dimensional molecular graph based on the drug's SMILES string and uses a graph convolutional neural network to encode the drug features. The protein encoder is based on a multi-order gated convolution, which enhances the model's ability to capture global feature between amino acid sequences. In order to better achieve interactive learning between drugs and proteins, we designed a multi-attention fusion module that effectively captures the drug-target interaction features. Experimental results show that MGMA-DTI outperforms other baseline models on three benchmark datasets: BindingDB, BioSNAP, and Human. Case studies further demonstrate that the model provides valuable insights for drug discovery. In addition, our model provides molecular-level interpretability, which can provide more scientifically meaningful guidance.

Artificial intelligence for small molecule anticancer drug discovery

INTRODUCTION

The transition from conventional cytotoxic chemotherapy to targeted cancer therapy with small-molecule anticancer drugs has enhanced treatment outcomes. This approach, which now dominates cancer treatment, has its advantages. Despite the regulatory approval of several targeted molecules for clinical use, challenges such as low response rates and drug resistance still persist. Conventional drug discovery methods are costly and time-consuming, necessitating more efficient approaches. The rise of artificial intelligence (AI) and access to large-scale datasets have revolutionized the field of small-molecule cancer drug discovery. Machine learning (ML), particularly deep learning (DL) techniques, enables the rapid identification and development of novel anticancer agents by analyzing vast amounts of genomic, proteomic, and imaging data to uncover hidden patterns and relationships.

AREA COVERED

In this review, the authors explore the important landmarks in the history of AI-driven drug discovery. They also highlight various applications in small-molecule cancer drug discovery, outline the challenges faced, and provide insights for future research.

EXPERT OPINION

The advent of big data has allowed AI to penetrate and enable innovations in almost every stage of medicine discovery, transforming the landscape of oncology research through the development of state-of-the-art algorithms and models. Despite challenges in data quality, model interpretability, and technical limitations, advancements promise breakthroughs in personalized and precision oncology, revolutionizing future cancer management.

SSLDTI: A novel method for drug-target interaction prediction based on self-supervised learning

Many computational methods have been proposed to identify potential drug-target interactions (DTIs) to expedite drug development. Graph neural network (GNN) methods are considered to be one of the most effective approaches. However, shallow GNN methods can only aggregate local information from nodes. Also, deep GNN methods may result in over-smoothing while obtaining long-distance neighbourhood information. As a result, existing GNN methods struggle to extract the complete features of the graph. Additionally, the number of known DTIs is insufficient, and there are far more unknown drug-target pairs than known DTIs, leading to class imbalance. This article proposes a model that combines graph autoencoder and self-supervised learning to accurately encode multilevel features of graphs using only a small number of labelled samples. We introduce a positive sample compensation coefficient to the objective function to mitigate the impact of class imbalance. Experiments on two datasets demonstrated that our model outperforms the four baseline methods, and the new DTIs predicted by the SSLDTI model were verified by the DrugBank database.

A journey from omics to clinicomics in solid cancers: Success stories and challenges

The word 'cancer' encompasses a heterogenous group of distinct disease types characterized by a spectrum of pathological features, genetic alterations and response to therapies. According to the World Health Organization, cancer is the second leading cause of death worldwide, responsible for one in six deaths and hence imposes a significant burden on global healthcare systems. High-throughput omics technologies combined with advanced imaging tools, have revolutionized our ability to interrogate the molecular landscape of tumors and has provided unprecedented understanding of the disease. Yet, there is a gap between basic research discoveries and their translation into clinically meaningful therapies for improving patient care. To bridge this gap, there is a need to analyse the vast amounts of high dimensional datasets from multi-omics platforms. The integration of multi-omics data with clinical information like patient history, histological examination and imaging has led to the novel concept of clinicomics and may expedite the bench-to-bedside transition in cancer. The journey from omics to clinicomics has gained momentum with development of radiomics which involves extracting quantitative features from medical imaging data with the help of deep learning and artificial intelligence (AI) tools. These features capture detailed information about the tumor's shape, texture, intensity, and spatial distribution. Together, the related fields of multiomics, translational bioinformatics, radiomics and clinicomics may provide evidence-based recommendations tailored to the individual cancer patient's molecular profile and clinical characteristics. In this chapter, we summarize multiomics studies in solid cancers with a specific focus on breast cancer. We also review machine learning and AI based algorithms and their use in cancer diagnosis, subtyping, prognosis and predicting treatment resistance and relapse.

Small molecule-mediated targeting of microRNAs for drug discovery: Experiments, computational techniques, and disease implications

Small molecules have been providing medical breakthroughs for human diseases for more than a century. Recently, identifying small molecule inhibitors that target microRNAs (miRNAs) has gained importance, despite the challenges posed by labour-intensive screening experiments and the significant efforts required for medicinal chemistry optimization. Numerous experimentally-verified cases have demonstrated the potential of miRNA-targeted small molecule inhibitors for disease treatment. This new approach is grounded in their posttranscriptional regulation of the expression of disease-associated genes. Reversing dysregulated gene expression using this mechanism may help control dysfunctional pathways. Furthermore, the ongoing improvement of algorithms has allowed for the integration of computational strategies built on top of laboratory-based data, facilitating a more precise and rational design and discovery of lead compounds. To complement the use of extensive pharmacogenomics data in prioritising potential drugs, our previous work introduced a computational approach based on only molecular sequences. Moreover, various computational tools for predicting molecular interactions in biological networks using similarity-based inference techniques have been accumulated in established studies. However, there are a limited number of comprehensive reviews covering both computational and experimental drug discovery processes. In this review, we outline a cohesive overview of both biological and computational applications in miRNA-targeted drug discovery, along with their disease implications and clinical significance. Finally, utilizing drug-target interaction (DTIs) data from DrugBank, we showcase the effectiveness of deep learning for obtaining the physicochemical characterization of DTIs.

Recent Advances in Deep Learning for Protein-Protein Interaction Analysis: A Comprehensive Review

Deep learning, a potent branch of artificial intelligence, is steadily leaving its transformative imprint across multiple disciplines. Within computational biology, it is expediting progress in the understanding of Protein-Protein Interactions (PPIs), key components governing a wide array of biological functionalities. Hence, an in-depth exploration of PPIs is crucial for decoding the intricate biological system dynamics and unveiling potential avenues for therapeutic interventions. As the deployment of deep learning techniques in PPI analysis proliferates at an accelerated pace, there exists an immediate demand for an exhaustive review that encapsulates and critically assesses these novel developments. Addressing this requirement, this review offers a detailed analysis of the literature from 2021 to 2023, highlighting the cutting-edge deep learning methodologies harnessed for PPI analysis. Thus, this review stands as a crucial reference for researchers in the discipline, presenting an overview of the recent studies in the field. This consolidation helps elucidate the dynamic paradigm of PPI analysis, the evolution of deep learning techniques, and their interdependent dynamics. This scrutiny is expected to serve as a vital aid for researchers, both well-established and newcomers, assisting them in maneuvering the rapidly shifting terrain of deep learning applications in PPI analysis.

mOWL: Python library for machine learning with biomedical ontologies

MOTIVATION

Ontologies contain formal and structured information about a domain and are widely used in bioinformatics for annotation and integration of data. Several methods use ontologies to provide background knowledge in machine learning tasks, which is of particular importance in bioinformatics. These methods rely on a set of common primitives that are not readily available in a software library; a library providing these primitives would facilitate the use of current machine learning methods with ontologies and the development of novel methods for other ontology-based biomedical applications.

RESULTS

We developed mOWL, a Python library for machine learning with ontologies formalized in the Web Ontology Language (OWL). mOWL implements ontology embedding methods that map information contained in formal knowledge bases and ontologies into vector spaces while preserving some of the properties and relations in ontologies, as well as methods to use these embeddings for similarity computation, deductive inference and zero-shot learning. We demonstrate mOWL on the knowledge-based prediction of protein-protein interactions using the gene ontology and gene-disease associations using phenotype ontologies.

AVAILABILITY AND IMPLEMENTATION

mOWL is freely available on https://github.com/bio-ontology-research-group/mowl and as a Python package in PyPi.

SUPPLEMENTARY INFORMATION

Supplementary data are available at Bioinformatics online.

DTSyn: a dual-transformer-based neural network to predict synergistic drug combinations

Drug combination therapies are superior to monotherapy for cancer treatment in many ways. Identifying novel drug combinations by screening is challenging for the wet-lab experiments due to the time-consuming process of the enormous search space of possible drug pairs. Thus, computational methods have been developed to predict drug pairs with potential synergistic functions. Notwithstanding the success of current models, understanding the mechanism of drug synergy from a chemical-gene-tissue interaction perspective lacks study, hindering current algorithms from drug mechanism study. Here, we proposed a deep neural network model termed DTSyn (Dual Transformer encoder model for drug pair Synergy prediction) based on a multi-head attention mechanism to identify novel drug combinations. We designed a fine-granularity transformer encoder to capture chemical substructure-gene and gene-gene associations and a coarse-granularity transformer encoder to extract chemical-chemical and chemical-cell line interactions. DTSyn achieved the highest receiver operating characteristic area under the curve of 0.73, 0.78. 0.82 and 0.81 on four different cross-validation tasks, outperforming all competing methods. Further, DTSyn achieved the best True Positive Rate (TPR) over five independent data sets. The ablation study showed that both transformer encoder blocks contributed to the performance of DTSyn. In addition, DTSyn can extract interactions among chemicals and cell lines, representing the potential mechanisms of drug action. By leveraging the attention mechanism and pretrained gene embeddings, DTSyn shows improved interpretability ability. Thus, we envision our model as a valuable tool to prioritize synergistic drug pairs with chemical and cell line gene expression profile.

Artificial intelligence in cancer target identification and drug discovery

Artificial intelligence is an advanced method to identify novel anticancer targets and discover novel drugs from biology networks because the networks can effectively preserve and quantify the interaction between components of cell systems underlying human diseases such as cancer. Here, we review and discuss how to employ artificial intelligence approaches to identify novel anticancer targets and discover drugs. First, we describe the scope of artificial intelligence biology analysis for novel anticancer target investigations. Second, we review and discuss the basic principles and theory of commonly used network-based and machine learning-based artificial intelligence algorithms. Finally, we showcase the applications of artificial intelligence approaches in cancer target identification and drug discovery. Taken together, the artificial intelligence models have provided us with a quantitative framework to study the relationship between network characteristics and cancer, thereby leading to the identification of potential anticancer targets and the discovery of novel drug candidates.